All News

The survey highlights the challenges and opportunities physicians encounter in hospital- and corporate-owned settings.

Hadley Wood, MD, shares her vision as the new editor-in-chief of Urology.

“The impressive duration of response, still expanding with 6/8 responses ongoing, is indicative of restoration of a lasting immunologic tumor control in advanced solid tumor patients,” says Eugen Leo, MD, PhD, MBA

“Our analysis suggests that there is superior clinical benefit with olaparib versus control both in patients who had and had not received previous taxane treatment,” said Maha Hussain, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

"In these studies, we were pleased to find that disitamab vedotin has consistent efficacy and manageable safety in patients with chemotherapy-refractory mUC," says Jun Guo, MD.

According to Neuspera, results from phase 2 of the SANS-UUI trial are expected to support an application for FDA approval of the device in patients with OAB-related UUI.

"I'm thrilled to continue my partnership with SMPA to educate and empower others to address their OAB," says Holly Robinson Peete.

The patents apply exclusively to the Ga-68 HBED-PSMA-11 production kit (Locametz), developed by Advance Accelerator Applications.

“The study highlights the importance of considering how altering cell metabolism could impact prostate cancer and its response to treatment," says Jenna Giafaglione.

Leading West Michigan practice now affiliated with nation’s largest urological healthcare management company

The designations, which will expedite the development and regulatory review of cretostimogene grenadenorepvec in this setting, are supported by results from the phase 3 BOND-003 trial.

The application is based on results from the phase 3 CheckMate-901 trial.

The designation, which will expedite the development and regulatory review of TAR-200 in this setting, is based on findings from the phase 2b SUNRISE-1 trial.

According to Clarity Pharmaceuticals, the final results are intended to support an application to the FDA for approval of 64Cu-SAR-bisPSMA for imaging in patients with prostate cancer.

Overall, Black men were 24% less likely to receive or be prescribed a novel hormonal therapy agent compared with White men.

"In the 21st century, expert witnesses serve a vital role in presenting evidence to a jury. A good expert will be able to distill complex information into digestible elements the jurors can understand," writes Austin Richards, Esq.

Taher Naeem, a fourth-year medical student at Baylor College of Medicine, highlights 3 abstracts that were presented during the 24th Annual Fall Scientific Meeting of the SMSNA in San Diego, California.

“Our experience with TULSA demonstrates substantial post-procedure decreases in PSA level, PSA density, and prostate volume,” the researchers wrote.

Small index lesions on initial multiparametric MRI were linked to a less aggressive clinical course for patients with prostate cancer on active surveillance.

The Bladder EpiCheck test received FDA 510(k) clearance in May 2023 for use in patients with NMIBC.

The investigators reported that “the risk of recurrence was significantly lower following BLC (HR=0.67, 95% CI: 0.51-0.89) than WLC.”

At 36 months’ follow-up the gene therapy nadofaragene firadenovec demonstrated durable complete responses in patients with high-risk, BCG-unresponsive non-muscle–invasive bladder cancer.

The priority review is based on results from the phase 3 EV-302 trial.

Primary chemoablative therapy with the mitomycin-containing reverse thermal gel UGN-102 induced complete responses in nearly 4 out of 5 patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.

The oncolytic immunotherapy cretostimogene grenadenorepvec induced complete responses in over three-fourths of patients with high-risk BCG-unresponsive non–muscle-invasive bladder cancer.

The data showed that Black, Hispanic, and uninsured patients were independently associated with a lower likelihood of receiving immunotherapy.

The investigators reported that pCR was significantly higher in the neoadjuvant chemotherapy + RNU group vs RNU alone, with an OR of 2.49 (95% CI: 1.75 – 3.54, P < .001).

PSMA-PET is becoming an invaluable tool for the diagnosis and management of oligometastatic prostate cancer patients, a sub-group for whom novel treatment strategies are continuing to emerge.